Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Novo Nordisk ( (NVO) ) has provided an announcement.
Novo Nordisk has successfully completed the acquisition of three manufacturing sites from Novo Holdings, following the latter’s acquisition of Catalent, Inc., a global contract development and manufacturing organization. This strategic move is set to enhance Novo Nordisk’s manufacturing capacity, complementing its internal supply chain expansions, thereby allowing the company to reach more individuals with serious chronic diseases. The acquisition is expected to have financial implications in 2024 and 2025, reflecting Novo Nordisk’s continued growth and strategic positioning within the healthcare industry.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. It focuses on defeating serious chronic diseases, particularly diabetes, through scientific breakthroughs, expanding access to medicines, and disease prevention and cure efforts. The company operates in 80 countries, marketing its products in around 170 countries, and employs about 72,000 people. Novo Nordisk’s shares are listed on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
YTD Price Performance: 5.22%
Average Trading Volume: 5,369,741
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $480.6B
See more insights into NVO stock on TipRanks’ Stock Analysis page.
